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 25 
ABSTRACT 26 
There is increasing interest recently in developing intranasal vaccines against respiratory tract 27 
infections. Antibody response is critical in vaccine-induced protection and TFH is considered 28 
important in mediating antibody response. Most data supporting the role for TFH in antibody response 29 
are from animal studies, and direct evidence from humans is limited, apart from TFH-like cells in 30 
blood. We studied activation and induction of TFH and its role on anti-influenza antibody response by 31 
live-attenuated influenza vaccine(LAIV) in human nasopharynx-associated lymphoid tissue(NALT). 32 
TFH activation in adenotonsillar tissues were analysed by flow-cytometry, and anti-33 
hemagglutinin(HA) antibodies examined following LAIV stimulation of tonsillar mononuclear 34 
cells(MNC). Induction of antigen-specific TFH by LAIV was studied by flow-cytometry for induced 35 
TFH and CD154 expression. LAIV induced TFH proliferation which correlated with anti-HA antibody 36 
production, and TFH was shown critical for antibody response. Induction of TFH from naïve T cells by 37 
LAIV was shown in newly induced TFH expressing BCL6 and CD21, which was followed by the 38 
detection of anti-HA antibodies. Antigen specificity of LAIV-induced TFH was demonstrated by the 39 
expression of antigen-specific T cell activation marker CD154 upon challenge by H1N1 virus antigen 40 
or HA. LAIV-induced TFH differentiation was inhibited by BCL6, IL21, ICOS and CD40 signalling 41 
blocking respectively, and that diminished anti-HA antibody production. Conclusion: We 42 
demonstrate for the first time the induction of antigen-specific TFH by LAIV in human NALT that 43 
provide critical support for anti-influenza antibody response. Promoting antigen-specific TFH in 44 
NALT by intranasal vaccines may provide an effective vaccination strategy against respiratory 45 
infections in humans.  46 
 47 
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IMPORTANCE. Airway infection such as influenza is common in humans. Intranasal vaccination has 48 
been considered a more biologically relevant and effective way of immunization against airway 49 
infection.  Vaccine-induced antibody response is crucial for protection against infection. Recent data 50 
from animal studies suggest one type of T cells, named TFH is important for the antibody response. 51 
However, data on whether this TFH-mediated help for antibody production operates in humans is 52 
limited, due to the lack of access to human immune tissue containing the TFH. In this study, we 53 
demonstrated the induction of TFH cells by an intranasal influenza vaccine in human immune tissue 54 
that provide critical support for anti-influenza antibody response. Our findings provide direct 55 
evidence that TFH cells play a critical role in vaccine-induced immunity in humans, and suggest a 56 
novel strategy to promote such cells by intranasal vaccines against respiratory infections.  57 
Keywords: T follicular helper cell (TFH), LAIV, influenza vaccine, mucosal immunity, antibody 58 
response, nasopharynx-associated lymphoid tissue (NALT) 59 
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INTRODUCTION 70 
Vaccination is one of the most effective preventative measures against pathogenic infection. Despite 71 
its success, there are still many infectious diseases in humans that lack effective vaccines. New 72 
strategies to improve vaccine immunogenicity are constantly being explored. Recent studies suggest 73 
a critical role for T follicular helper cells (TFH) in vaccine-induced immunity (1, 2) and promoting 74 
TFH has been considered a promising vaccination strategy. However, most of the current evidence 75 
supporting the importance of TFH in vaccination comes from animal studies, and direct evidence from 76 
humans is limited, apart from the detection of TFH-like cells from human peripheral blood samples 77 
which are thought as TFH equivalent (3, 4). Whether this TFH–mediated critical help for vaccine-78 
induced B cell antibody response operates in humans remain largely unsubstantiated. Several recent 79 
studies have reported that the presence of “TFH -like” cells in peripheral blood following parenteral 80 
influenza vaccination appeared to correlate with an anti-hemagglutinin (HA) antibody response (5, 81 
6). 82 
TFH are a subset of CD4+ T cells in secondary lymphoid tissue that provide help to cognate B cells 83 
for high affinity antibody production in germinal centers (GC) and for long-term humoral 84 
immunity(7). TFH express chemokine receptor CXCR5 and inducible costimulator-ICOS, IL21 and 85 
the transcription factor B-cell lymphoma 6 (BCL6) (8). Considering the importance of TFH for B cell 86 
antibody response, novel vaccines to induce/activate TFH cells may be an effective vaccination 87 
strategy for better vaccine efficacy in humans. 88 
Influenza virus infects nasopharyngeal mucosa by binding its surface HA to sialic acid receptors on 89 
the host cell (9). Intranasal vaccination has been proposed as an effective way of immunising against 90 
influenza through induction of anti-HA antibody, which relies on the local mucosal immune tissue, 91 
i.e. nasopharynx-associated lymphoid tissue (NALT) as the induction site for immunity. Human 92 
adenoids and tonsils are major components of NALT and are known to be major induction sites for 93 
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both mucosal and systemic immunity against upper respiratory tract pathogens including influenza 94 
virus (10-13).  95 
Live Attenuated Influenza Vaccines (LAIV) are administered as intranasal sprays and comprise of 96 
live-attenuated influenza type A (H1N1 and H3N2), and type B viruses. LAIV has been used in a 97 
number of countries including USA and Canada (FluMist®) (14), and in Europe (Fluenz™), and been 98 
shown to induce both mucosal and serum antibodies, as well as cellular immune responses (15-17).  99 
Although LAIV has been shown to be effective against influenza (18), limited data are available on 100 
the induction of LAIV-induced immunity in humans and on how the anti-HA antibody response is 101 
regulated by T cells. We have studied the activation and induction of TFH by LAIV and its role on the 102 
anti-HA antibody response in human NALT tissue, and shown the induction of antigen-specific TFH 103 
in NALT is critical in LAIV-induced anti-influenza HA antibody response.  104 
 105 
RESULTS 106 
LAIV activates a proliferative TFH response in NALT that provides critical help for anti-HA 107 
antibody production  108 
Activation of TFH in NALT was examined by LAIV stimulation of adenotonsillar MNC for 3 days 109 
followed by enumerating TFH numbers using flow cytometry. As shown in Figure 1a+b, LAIV 110 
stimulation elicited a significant increase in TFH number (CD4+CXCR5hiICOShi) compared to 111 
unstimulated control (p<0.01). The TFH response was further assessed by analysis of T cell 112 
proliferation using CFSE cell tracing. As can be seen in Figure 1c+d, stimulation of tonsillar MNC 113 
by LAIV elicited a marked TFH proliferative response detected at day 5 of cell culture (p<0.001). 114 
Further analysis also demonstrated a marked increase in the number of germinal center B cells 115 
(CD19+CD38+IgD-) following LAIV stimulation (Fig 1e+f, p<0.01). 116 
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Anti-influenza antibody production was measured in tonsillar MNC culture supernatant following 117 
LAIV stimulation for 8 days. As expected, LAIV elicited marked anti-HA antibody production (Fig 118 
1g), and T- B cell co-culture experiment demonstrated B cells co-cultured with purified TFH elicited 119 
anti-HA antibody production, whereas no antibody production was shown in B cells co-cultured with 120 
non-TFH (CXCR5-CD4+) cells (Fig 1h).  121 
Induction of antigen-specific TFH by LAIV that correlates with antibody production  122 
To determine whether LAIV induces TFH differentiation from naive CD4+ T cells in NALT, tonsillar 123 
MNC depleted of CD45RO+ T cells (resulting in CD45RO- MNC) were stimulated for 7 days with 124 
LAIV. The CD45RO- MNC contained naive T cells but without CD45RO+ cells including CXCR5+ 125 
TFH. As shown in Figure 2a+b, LAIV stimulation of CD45RO
- MNC induced a marked increase in 126 
the number of CD4+ICOS+CXCR5+ (TFH) cells following 7 days of cell culture. The induced TFH 127 
were shown to express the transcription factor BCL6 and cytokine IL21 (Fig 2c+d). The induction of 128 
TFH by LAIV was shown in a dose-dependent fashion (Fig 2e, top), which was accompanied by a 129 
dose-dependent increase in anti-HA IgG antibody production in the cell culture supernatant detected 130 
at day 14 (2e, bottom). All the 3 major antibody isotypes including IgG, IgM and IgA anti-HA 131 
antibodies were detected in the culture supernatant at day 14 following LAIV stimulation (Fig 2f). 132 
Having shown the induction of TFH by LAIV, we next examined the specificity of these induced TFH 133 
for influenza antigens. As CD154 is considered a reliable functional marker for antigen-activated T 134 
cells, i.e. a marker for antigen-specific T cells (5, 19-21), CD154 expression in the CD4+ T cell 135 
subsets was analyzed following either an inactivated sH1N1 virus antigen or recombinant HA 136 
challenge. A representative dot plot demonstrating the activated TFH (ICOS+CXCR5+, top right 137 
quadrant) following the antigen challenge was shown in Fig 3a, and the frequencies of activated TFH 138 
(% of CD4+ T cell) following sH1N1 antigen or HA challenge were shown in Fig 3b. Both antigen 139 
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stimulations activated a marked increase in the TFH numbers compared to non-antigen control, and as 140 
expected, the sH1N1 virus antigen challenge elicited a higher increase in TFH frequency than HA 141 
(3b). Among the activated TFH cells following sH1N1 challenge, a large proportion (mean 62.2%) 142 
expressed CD154 (3c+d), demonstrating the high frequency of activated influenza antigen–specific 143 
T cells in these TFH,  substantially higher than the other non-TFH CD4+ cell populations:  0.45% in 144 
ICOS-CXCR5-, 3.05% in ICOS-CXCR5+, and 20.6% in ICOS+CXCR5- populations (p<0.001, 145 
p<0.001 and p<0.01 respectively) (Fig 3c+d). A similar proportions of CD154+ CD4+ T cell 146 
populations including CD154+ TFH were shown following the HA antigen challenge (data not shown). 147 
LAIV-activated induction of TFH in NALT involves IL21, ICOS, CD40 and BCL6 signalling,   148 
As LAIV induced TFH cells expressed a high level of IL21 and ICOS, we determined whether the TFH 149 
induction from naïve T cells involved IL21R and ICOS signalling. Co-incubation of naïve T cell-150 
containing CD45RO- MNC with either IL21R or ICOS-Ligand blocking antibody led to a marked 151 
reduction in TFH cell induction by LAIV respectively (Fig 3e, p<0.01). Further, co-incubation with 152 
CD40-ligand blocking antibody or a BCL6 inhibitor also led to a marked reduction in the TFH 153 
induction (3e). Finally, co-incubation with anti-IL21R, ICOS-L and CD40-L antibodies or the BCL6 154 
blocker respectively inhibited the LAIV-induced anti-HA antibody production in CD45RO- MNC 155 
(3f, p<0.01). 156 
IL-21 production by LAIV-activated TFH is critical for anti-HA antibody production  157 
We next examined the cellular source and production of IL21 in tonsillar MNC following LAIV 158 
stimulation, and its effect on TFH activation and antibody production. Among tonsillar lymphocytes, 159 
TFH were shown as a predominant source of IL21 (4a). Following LAIV stimulation there was an 160 
increase of IL21-producing TFH in tonsillar MNC (Fig 4b), together with a marked increase in IL21 161 
concentration in the MNC culture supernatant (4c). Further, the increase in IL21 concentration was 162 
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shown in the co-culture of TFH and B cells (4d), but not seen in the co-culture of non-TFH with B cells 163 
following LAIV stimulation (4e). 164 
IL21 receptor blocking using anti-IL21R antibody abrogated the increase of TFH number in tonsillar 165 
MNC elicited by LAIV stimulation (4f), followed by a significant reduction in anti-HA antibody 166 
production in tonsillar MNC (4g). 167 
Activation of TFH–like cells in PBMC by LAIV  168 
Recent studies suggest there are TFH-like cells in peripheral blood that express CXCR5 and ICOS and 169 
have similar B cell-help functions (5, 22-25). To determine whether LAIV activate TFH-like cells and 170 
antibody production in peripheral blood, freshly isolated PBMC were stimulated by LAIV for up to 171 
14 days followed by flow-cytometry and antibody detection. As shown in figure 5a+b, LAIV 172 
stimulation induced an increase of TFH–like (CXCR5+ICOS+) CD4+ T cells in PBMC (at day 7), 173 
followed by the detection of anti-HA IgG and IgM antibodies in the PBMC culture supernatants (Fig 174 
5c). The activation of influenza antigen-specific TFH–like cells by LAIV was demonstrated by the 175 
finding that a major proportion (mean 45.6%) of these cells expressed CD154 following the H1N1 176 
antigen challenge, markedly higher than the other non-TFH cell populations (Fig 5d).  177 
DISCUSSION 178 
LAIV is thought to replicate in upper respiratory tract to induce immunity through the local immune 179 
tissue NALT, and it was shown to replicate in nasal epithelial cells(26). As part of the mucosal 180 
immune system in human nasopharynx, adenotonsillar tissue has a surface reticular epithelial cell 181 
layer in which epithelial cells mixed with other cells including a large number of B cells. Many B 182 
cells infiltrating the epithelial layer exhibit memory B cell markers and have great antigen-presenting 183 
potential(27, 28). In our adenotonsillar MNC culture, the predominant cell populations are 184 
lymphocytes of which over 50% are B cells(29). We previously showed a Modified Vaccinia 185 
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Virus Ankara(MVA) vectored influenza vaccine predominantly infected tonsillar B cells which were 186 
also the major cells presenting vaccine antigens(30). It is likely tonsillar B cells are a major cell 187 
population involved in LAIV replication and antigen presentation to T cells, and this B and T cell 188 
interaction contributes to the vaccine-induced response in NALT. Our recent pilot data showed a 189 
time-dependent increase in HA expression in tonsillar B cells following LAIV stimulation, consistent 190 
with virus replication in tonsillar B cells. Fetal bovine serum(10%) was used in our cell culture, and 191 
we did not find any evidence suggesting blockade of LAIV replication(data not shown). 192 
In this study, we have demonstrated the activation and induction of antigen-specific TFH in human 193 
nasopharynx immune tissue by LAIV, and show TFH are critical for LAIV-induced B cell anti-HA 194 
antibody response in the immune induction tissue of children and adults.  195 
We showed a marked increase in TFH number in tonsillar MNC following stimulation by LAIV (Fig 196 
1a+b). With CFSE cell tracing, we also demonstrated TFH proliferation following the stimulation (Fig 197 
1c+d). The increase in TFH number was accompanied by the production of anti-HA antibodies in 198 
tonsillar MNC (Fig 1g). We further demonstrated in the cell co-culture experiment that purified TFH 199 
from tonsillar MNC helped B cell anti-HA antibody production, whereas non-TFH cells did not (Fig 200 
1h). These results support that TFH provide critical help for LAIV-induced B cell anti-HA antibody 201 
production in human NALT. 202 
Together with the increase in TFH and antibody production following LAIV stimulation, a marked 203 
increase in GC B cells was also seen in tonsillar MNC (Fig 1e+f). This is consistent with the 204 
assumption that LAIV activates TFH which support GC B cell proliferation and differentiation for 205 
antibody production. We reported previously that the number of TFH correlated with that of GC B 206 
cells in NALT (20). These are concordant with previous reports in mouse models that GC B cells 207 
correlated with the appearance of TFH after influenza virus infection (31) and the magnitude of TFH 208 
response was directly correlated with the GC B cell response (32, 33).  209 
 o
n
 April 6, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://jvi.asm.org/
D
ow
nloaded from
 
10 
 
We next examined the induction of influenza antigen-specific TFH from naïve T cells by LAIV using 210 
TFH-depleted CD45RO- MNC. 7 days following LAIV stimulation, we have observed a dose-211 
dependent increase in the number of newly differentiated TFH (CXCR5+ICOS+) that co-expressed 212 
BCL6 and IL21, which was followed by the detection of anti-HA antibody at day 14 (Fig 2a-e). Both 213 
BCL6 and IL21 are known to be essential for TFH differentiation from naïve T cells in animal studies 214 
(8, 34, 35).  Our results here support TFH induction in human immune tissue also requires BCL6 and 215 
IL21.  Indeed, further experiment with BCL6 blocker and IL21 blocking antibody demonstrated 216 
marked reduction of TFH induction from naïve tonsillar T cells, confirming a critical role of BCL6 217 
and IL21 in TFH induction. We also showed ICOS signalling blocking inhibited ICOS activation and 218 
TFH induction, supporting that ICOS activation is required in TFH differentiation. It has been suggested 219 
that CD4+ T cells utilize ICOS:ICOSL interactions to upregulate IL21 production through which to 220 
contribute to TFH induction (35).  Our finding that CD40L blocking antibody abrogated TFH induction 221 
is in line with the hypothesis that B and T cell cognate interaction through CD40:CD40L signalling 222 
is critical in TFH induction.  223 
One finding we observed was that CD45RO+ cell depletion, which removes memory T cells from 224 
tonsillar MNC, markedly reduced anti-HA antibody production analysed at day 8 (for memory 225 
response).  The fact that anti-HA IgG level could be readily detected at a high level in whole tonsillar 226 
MNC following vaccine stimulation at day 8 (Fig 1g), whereas in memory T cell-depleted MNC the 227 
antibody production could only be detected at around day 14 at a lower level (Fig 2f) suggests the 228 
presence of influenza-specific memory T/B cells in tonsillar MNC.  In this study, although tonsillar 229 
tissues were from non-vaccinated donors, it is likely some of the donors had experienced an influenza 230 
infection previously, and had influenza-specific memory T/B cells. Therefore the presence of the 231 
memory T cells including Tfh in tonsillar MNC helped the memory B cell response following LAIV 232 
stimulation.  233 
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Further to the reduction of TFH induction following BCL6, IL21, ICOS and CD40L signalling 234 
blocking, we showed that the blockade of these signallings led to a diminished anti-HA antibody 235 
production, supporting the critical involvement of these pathways in TFH induction and TFH-mediated 236 
B cell antibody production. The induction of influenza antigen-specific TFH by LAIV was 237 
demonstrated by the detection of antigen-specific CD4+ T cell activation marker CD154, which was 238 
expressed in a large proportion of the induced TFH following influenza antigen challenge (Fig 3). This 239 
finding is consistent with the report by Bentebibel et al demonstrating the increase in influenza 240 
antigen-specific TFH-like cells in peripheral blood following an inactivated vaccine immunization in 241 
humans (5).  242 
Studies in animal model demonstrated a critical role of IL21 in TFH activation and TFH were also 243 
shown to be the predominant source of IL21(34, 36). We showed here that stimulation of tonsillar 244 
MNC with LAIV activated a marked increase in IL21-producing TFH and in IL21 concentration in 245 
the cell culture supernatant. These results are consistent with the assumption that TFH are a major 246 
cellular source of IL21 in human tonsillar lymphocytes, as we found no significant IL21 production 247 
in the absence of TFH in the T-B cell co-culture experiment (Fig 4). We also demonstrated that newly 248 
differentiated TFH following LAIV stimulation expressed a high level of IL21 (Fig 2). As tonsillar 249 
TFH were also known to express IL21R (35), this co-expression of IL21 and IL21R by tonsillar TFH 250 
supports the hypothesis that IL21 acts in an autocrine-loop fashion in the vaccine-induced TFH 251 
differentiation and function in human NALT. Indeed, we showed that blocking IL21 signalling by an 252 
IL-21R neutralizing antibody inhibited both activation and differentiation of TFH induced by LAIV, 253 
and that diminished the anti-HA antibody production. So our results provide direct supporting 254 
evidence that IL21 is crucial in vaccine-induced TFH differentiation, and in TFH-dependent B cell 255 
antibody production in human immune tissue.  256 
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Consistent with recent reports that there was an increase in TFH-like cells in human peripheral blood 257 
following parenteral influenza vaccination which correlated with the anti-HA antibody response (5, 258 
6), we showed LAIV stimulation of PBMC also induced an increase in CXC5+ TFH-like cells together 259 
with the production in anti-HA antibodies in the PBMC (Fig 5). The activation of influenza antigen-260 
specific TFH in PBMC by LAIV was demonstrated by the expression of antigen-specific T cell 261 
activation marker CD154 upon antigen challenge. These results support the concept that there are 262 
TFH-like cells in peripheral circulation which are functionally similar to TFH found in lymphoid tissue 263 
such as NALT,  and provide help to B cells for antibody production in an IL21- and ICOS-dependent 264 
manner (22).  265 
In conclusion, we demonstrate for the first time the induction of antigen-specific TFH in human 266 
immune tissue by an intranasal influenza vaccine, and show its critical role in the anti-influenza HA 267 
antibody response. Our results suggest promoting antigen-specific TFH in human NALT by intranasal 268 
vaccines may provide an effective vaccination strategy against respiratory infections in humans.  269 
 270 
 METHODS 271 
Patients and samples. Patients (age 2–30 years) undergoing adenoidectomy and/or tonsillectomy due 272 
to upper airway obstruction were recruited, and adenotonsillar tissues obtained following operation. 273 
A peripheral blood sample was also obtained before operation. The tonsillar tissues were transported 274 
in HBSS medium (Hank’s Balanced salt solution) to the laboratory. Tissue samples exhibiting any 275 
signs of gross inflammation were excluded. Patients with any known immunodeficiency were 276 
excluded from the study. Subjects who received influenza vaccination previously were also excluded 277 
from the study. The Liverpool Paediatric Research Ethics Committee approved the study 278 
[08/H1002/92] and written informed consent was obtained in each case. 279 
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LAIV vaccine and influenza antigens. An intranasal LAIV (FluMist, 2009-10) that included 280 
A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2) and B influenza strains was obtained from 281 
BEI resources (ATCC, Manassas,VA). 0.2ml of LAIV contains approximately 107 fluorescent focus 282 
units (FFU) of each strain, and we used 2µl/ml (105FFU/ml) in cell stimulation which was a 283 
predetermined optimal concentration for the activation of anti-HA antibody response following dose 284 
titration experiments. An inactivated seasonal A/Brisbane/59/2007 H1N1 influenza virus (sH1N1) 285 
antigen, which was inactivated by β-propiolactone and partially purified (37) was obtained from the 286 
National Institute for Biological Standards and Control (NIBSC, UK). This inactivated sH1N1 287 
antigen contained 83ug/ml of HA. A purified recombinant HA of sH1N1 (ATCC) was used for HA 288 
antigen stimulation as well as the coating antigen for anti-HA antibody measurement by ELISA. The 289 
recombinant HA contained a C-terminal histidine tag and were produced in High Five insect cells 290 
using a baculovirus expression vector system, purified from cell culture supernatant by immobilized-291 
metal affinity chromatography (IMAC) and contain a trimerizing (foldon) domain (38). 292 
Cell culture and stimulation. Mononuclear cells (MNC) from adenotonsillar tissues were isolated 293 
using Ficoll density centrifugation (39) (40). In some experiments, tonsillar MNC were depleted of 294 
effector and memory (CD45RO+) T cells using CD45RO microbeads and magnetic cell sorting 295 
(Miltenyi) by passing cells through the depletion column twice as described previously (41, 42). The 296 
depletion of CD45RO+ cells from tonsillar MNC removed TFH cells (>98%). Unfractionated whole 297 
MNC or CD45RO+cell-depleted MNC were cultured (4x106/ml) in RPMI-1640 medium 298 
supplemented with 10% fetal bovine serum (FBS), streptomycin (50μg/ml) and penicillin (50U/ml) 299 
(Sigma), in the presence the LAIV (2µl/ml unless otherwise stated) for up to 14 days. Cells were 300 
collected at pre-defined time points for analysis of TFH cells by flow-cytometry. Cell culture 301 
supernatants were collected for measurement of cytokine and antibody production respectively by 302 
ELISA.  303 
 o
n
 April 6, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://jvi.asm.org/
D
ow
nloaded from
 
14 
 
Flow-cytometry analysis of TFH, cell proliferation and intracellular cytokine expression. For TFH 304 
identification, tonsillar MNC were stained with anti-human CD3, CD4, CXCR5 and ICOS antibodies 305 
followed by flow cytometry and CD4+ CXCR5hi ICOShi cells were identified as TFH (43, 44). The 306 
tonsillar lymphocytes gated for analysis based on typical FSC/SSC characteristics and singlet 307 
selection has a typical viability >98% viability when examined with propidium iodide staining. 308 
Expression of B-cell lymphoma 6 protein (BCL6), a master transcription factor for TFH differentiation 309 
(8), in newly induced TFH cells was analyzed by intracellular staining with anti-human BCL6 antibody 310 
after cell fixation/permeabilization following manufacturer’ instructions (eBioscience). Cell 311 
proliferation was examined by Carboxyfluorescein succinimidyl ester (CFSE) staining of tonsillar 312 
MNC (Molecular Probes), followed by cell stimulation for 5 days and by flow cytometry (41, 42). 313 
Briefly, tonsillar MNC were labelled with CFSE (at 37°C, for 8 min) and resuspended in RPMI before 314 
cell stimulation with LAIV (2μl /ml) for 5 days. TFH cell proliferation was then examined by analysis 315 
of CFSE dilution in TFH cells (CXCR5hi ICOShi cells) by flow cytometry. Intracellular cytokine 316 
expression e.g. IL21 was analysed following a standard intracellular staining procedure including cell 317 
permeabilization as described previously (40). Flow cytometry data analyzed using FlowJo software. 318 
Germinal center (GC) B cell subset was analyzed by flow-cytometry with a combination of CD19, 319 
CD38 and IgD fluorescence-labelled anti-human antibodies and identified as CD19+CD38hiIgD-.  320 
Analysis of antigen-specific TFH induction. TFH differentiation/induction from naïve tonsillar T cells 321 
by LAIV was examined using CD45RO+cell-depleted MNC (which resulted in CD45RO- MNC) as 322 
described earlier. The CD45RO- MNC (with TFH removed but retained naïve T cell) were stimulated 323 
with LAIV (2µl/ml, otherwise as stated) and cultured for 7 days before flow-cytometric analysis for 324 
TFH cells including CXCR5, ICOS and BCL6 expressions. For the detection of induced influenza 325 
antigen-specific TFH cells after LAIV stimulation, the cells (at day 7) were washed and incubated for 326 
24 hours in fresh culture medium only, followed by antigen challenge with sH1N1 virus antigen or 327 
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recombinant HA (1µg/ml) for 6 hours in the presence of brefeldin A. The cells were then stained for 328 
TFH including CD4, CXCR5, ICOS, and intracellular CD154 expression after cell 329 
fixation/permeabilization which detects antigen-specific T cells by flow cytometry (19-21).  330 
To determine if IL21, ICOS, CD40 and BCL6 signalling pathways are involved in the 331 
activation/induction of TFH, neutralizing/blocking antibodies to IL21 receptor, ICOS- and CD40-332 
ligand (L) or a BCL6 inhibitor were used to co-incubate with tonsillar MNC before LAIV stimulation. 333 
Briefly, recombinant human IL21R-Fc chimera, anti-ICOS-L (R&D systems) and anti-CD40-L 334 
antibodies (InvivoGen) or isotype controls (10µg/ml) or BCL6 inhibitor (79-6, Calbiochem)(50 µM) 335 
were co-incubated with tonsillar MNC or CD45RO- MNC for 1 hour prior to stimulation by LAIV. 336 
BCL6 inhibitor 79-6 is a cell-permeable compound that selectively inhibits the transcriptional 337 
repression activity of BCL6. The MNC were then cultured for up to 7-14 days before analysis for TFH 338 
and anti-HA antibody production. 339 
Measurement of HA-Specific antibodies. Production of anti-HA IgG, IgM and IgA antibodies to 340 
sH1N1 virus in cell culture supernatants was measured as previously described (45, 46). In brief, 341 
ELISA plates were coated with recombinant sH1N1 HA overnight. Following blocking, cell culture 342 
supernatants were added and incubated for 2 hours. Alkaline phosphatase-conjugated anti-human 343 
IgG, IgM or IgA antibody was then added and incubated. Following the addition of pNPP substrate, 344 
color development was read at OD405nm at 1 hour and data were analysed using DeltaSoft software. 345 
Intravenous immunoglobulin (IVIG, Intratect ) containing high titers of anti-sH1N1 HA IgG antibody 346 
was used as a reference standard for IgG antibody. Anti-HA IgM and IgA antibody titers were 347 
expressed as OD values (read at 30min) as no reference standard was available.  348 
Cell purification and TFH-B cell co-culture. Tonsillar TFH and B cells were purified using magnetic 349 
cell sorting as described previously (43). Briefly, B cells were purified by negative selection using B 350 
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cell purification kit (EasySep™, Stemcell) which yielded B cell purity >99%. For TFH purification, 351 
CD4+T cells were first isolated by negative selection, followed by positive selection of CXCR5high 352 
(TFH) using biotin anti-CXCR5 antibody. The amount of anti-CXCR5 antibody was optimised to 353 
ensure only CXCR5high-expressing cells were selected (purity>95%). CXCR5- CD4+T (non-TFH) cells 354 
were isolated by negative selection from CD4+T cells using an optimised amount of anti-CXCR5 355 
antibody (purity >99%). Purified B cells were co-cultured (1:1 ratio) with either purified TFH or non-356 
TFH cells at 5x105 cells/ml in the presence of LAIV. The cells were cultured for 10 days and cell 357 
culture supernatants were collected for anti-HA antibody analysis.  358 
Statistical Analysis. Means and standard errors are used unless indicated otherwise. Differences 359 
between two groups were analysed using Student’s t test, and paired T test was used for paired 360 
samples. Statistical analysis was performed using GraphPad Prism 5 software. P<0.05 was considered 361 
statistically significant.  362 
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 504 
Figure legends 505 
Figure 1. LAIV induces TFH proliferation that correlates with GC B cell response and antibody 506 
production in NALT. LAIV stimulation induced an increase in TFH number (a+b) and TFH 507 
proliferation (c+d) in tonsillar MNC (b & d, n=15, **p<0.01 vs unstimulated medium controls).  (a 508 
& c)  Representative plots or histogram of TFH subset (CXCR5hi/ICOShi) in CD4+ T cells following 509 
stimulation (a, day 3), and TFH proliferation analysed by CFSE (c, day 5, red line: LAIV, grey shaded: 510 
medium control). (e & f)  Increase in GC B cell number (CD19+ CD38hi IgD-) in tonsillar MNC after 511 
LAIV stimulation (n=13, **P < 0.01 vs control). LAIV-induced anti-HA IgG antibody production in 512 
tonsillar MNC (g, n=20, **p<0.01 vs control, day 8), and LAIV-induced anti-HA IgG production in 513 
B cells co-cultured with TFH (red bar) or with non-TFH cells (blank bar) (h, n=10, **p<0.01, #p>0.05 514 
vs control). Data in the bar figures are means and SE from a number of different experiments done 515 
with tonsils from different donors. 516 
 517 
Figure 2. Induction of TFH from naïve tonsillar T cells and antibody production by LAIV. 518 
Representative plots (a) and bar graph (b) show the induction of TFH (CD4+CXCR5+ICOS+) from 519 
CD45RO-ve MNC by LAIV compared with medium control (n=10, **p<0.01).  (c & d) FACS 520 
histograms of BCL6 (c) and IL21 expression (d) in LAIV-induced TFH as compared to unstimulated 521 
medium control) (isotype controls: shaded).  (e) Dose-dependent induction of TFH (day 7, top) and 522 
anti-HA IgG antibody production (day 14, bottom) from CD45RO-ve MNC following LAIV 523 
stimulation (n=6). (f) LAIV-induced anti-HA IgG, IgM and IgA production in CD45RO-ve MNC (day 524 
14,  n=10, **p<0.01). 525 
 526 
Figure 3.  Detection of LAIV-induced antigen-specific TFH and effect of IL21, ICOS, CD40 and 527 
BCL6 signallings on TFH and antibody induction. CD45RO
-ve MNC were first stimulated by LAIV 528 
for 7 days followed by influenza antigen challenge with sH1N1 or HA antigen.  (a) A representative 529 
plot showing activated TFH (ICOS+CXCR5+) following sH1N1 antigen challenge, and (b) showing 530 
the frequencies of activated TFH (% of CD4+ T cell) after sH1N1 or HA challenge following prior 531 
LAIV stimulation (**p<0.01, ***p<0.001 vs LAIV stimulation alone. Medium alone negative 532 
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control is also shown). Representative plots (c) and summary frequency (d, n=5) of CD154+ 533 
expression in the CD4+ T cell subsets including TFH following sH1N1 antigen challenge. (e+f) 534 
Effect of neutralizing antibodies to IL21R, ICOS-and CD40-L or BCL6 blocker on TFH induction 535 
(e, day 7) and antibody production (f, day 14) in CD45RO-ve MNC following LAIV stimulation 536 
(**p<0.01 vs LAIV stimulation or isotype control antibodies). 537 
Figure 4. IL-21 expression in LAIV-activated TFH and its effect on anti-HA antibody production. 538 
(a) Representative plots showing TFH subset and IL21 expression in tonsillar CD4+ T cells following 539 
LAIV stimulation (shaded histogram: isotype control). (b)An increase in IL-21-producing TFH (% of 540 
CD4+ T cells) of tonsillar MNC following LAIV stimulation (n=10, **P < 0.01 vs control). (c-e) 541 
IL21 concentrations following stimulation in the culture supernatants of tonsillar MNC (c, n=22), of 542 
B cells co-cultured with TFH (d, n=10) or with non-TFH cells (e, n=10) (**P < 0.01 vs control, NS: 543 
not significant). (f+g) IL-21R blocking by adding anti-IL-21R antibody to tonsillar MNC led to a 544 
reduction in TFH number (f) and in anti-HA IgG, IgM and IgA antibody production (g) (n=8, 545 
**p<0.01). 546 
Figure 5. Activation of TFH–like cells in PBMC. (a) Representative plots shows the increase of TFH–547 
like cells (CD4+CXCR5+ICOS+) in PBMC following stimulation for 3 days by LAIV, as compared 548 
to medium control.  (b) LAIV-induced increase in TFH–like cells in PBMC compared with control 549 
(n=10, **P < 0.01). (c) Anti-HA IgG and IgM antibody production in PBMC culture supernatant 550 
following LAIV stimulation (n=10, **P < 0.01). (d) Frequency of antigen-specific CD154+ TFH–like 551 
cells (% of CD4+ T cells, red bar) in PBMC following LAIV stimulation and subsequent sH1N1 552 
antigen challenge, compared to other CD4+ T cell sub-populations as indicated (n=4,**p<0.01, 553 
***p<0.001). 554 
 555 
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